{'fraction_non_alphanumeric': 0.022222222222222223, 'fraction_numerical': 0.0, 'mean_word_length': 5.330578512396694, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes.

A number of protease inhibitors (PIs) are dependent on an acidic gastric pH for optimal drug dissolution and absorption. As a result, the potential for negative drug interactions with acid-reducing agents exists and could lead to subtnerapeutic drug concentrations, viral breakthrough, and development of drug resistance. Pharmacokinetic evaluations of a number of PIs given with acid-reducing agents have been performed and show varying degrees of effect. Given the possibility of decreases in PI exposures, clinicians should be aware of the potential for a negative interaction when selecting PI-based HAART for patients taking acid-reducing agents.